Tanvex BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,393	376.96	380.75	786.23	2,223	2,069
Cash & Short-Term Investments	1,393	376.96	380.75	786.23	2,223	2,069
Cash Growth	87.72%	-1.00%	-51.57%	-64.63%	7.46%	-14.78%
Accounts Receivable	119.03	0.07	9.4	0.33	2.52	-
Other Receivables	95.17	31.58	27.43	27.36	25.31	25.57
Receivables	214.21	31.65	36.83	27.69	27.84	25.57
Inventory	410.27	217.84	108.29	170.84	90.33	50.08
Prepaid Expenses	39.56	49.18	78.35	58.95	60.85	119.25
Total Current Assets	2,062	675.62	604.21	1,044	2,402	2,264
Property, Plant & Equipment	2,359	1,827	1,928	2,151	2,114	1,906
Other Intangible Assets	496.29	7.07	3.38	12.07	10.17	11.96
Other Long-Term Assets	421.31	225.3	227.67	213.47	187.58	190.98
Total Assets	8,175	2,735	2,763	3,420	4,714	4,373
Accounts Payable	42.89	-	-	-	-	-
Accrued Expenses	127.22	134.27	-	115.93	137.49	210.99
Current Portion of Long-Term Debt	-	-	-	-	-	54.77
Current Portion of Leases	173.09	160.01	163.45	124.65	88.75	65.74
Current Income Taxes Payable	26.89	-	-	-	-	-
Current Unearned Revenue	98.59	11.11	6.91	28.07	-	-
Other Current Liabilities	225.7	42.75	193.38	34.63	22.28	21.6
Total Current Liabilities	694.38	348.14	363.73	303.29	248.51	353.1
Long-Term Debt	-	-	-	-	-	35.53
Long-Term Leases	1,373	1,488	1,568	1,715	1,670	1,363
Long-Term Unearned Revenue	104.02	5.47	10.23	-	-	-
Other Long-Term Liabilities	1.72	-	-	10.47	-	-
Total Liabilities	2,173	1,842	1,942	2,028	1,919	1,752
Common Stock	2,648	1,641	1,340	3,527	3,525	3,116
Additional Paid-In Capital	18,898	13,567	12,431	11,061	10,988	9,653
Retained Earnings	-15,216	-14,136	-12,755	-12,969	-11,327	-9,784
Comprehensive Income & Other	-328.32	-177.94	-194.17	-227.09	-390.12	-364.04
Shareholders' Equity	6,002	893.31	821.11	1,391	2,795	2,621
Total Liabilities & Equity	8,175	2,735	2,763	3,420	4,714	4,373
Total Debt	1,546	1,648	1,732	1,839	1,759	1,519
Net Cash (Debt)	-153.42	-1,271	-1,351	-1,053	463.95	549.19
Net Cash Growth	-	-	-	-	-15.52%	-73.66%
Net Cash Per Share	-0.70	-8.19	-10.48	-8.95	4.27	6.14
Filing Date Shares Outstanding	264.82	164.07	133.96	117.64	117.57	103.95
Total Common Shares Outstanding	264.82	164.07	133.96	117.64	117.57	103.95
Working Capital	1,367	327.48	240.48	740.43	2,153	1,910
Book Value Per Share	22.66	5.44	6.13	11.83	23.77	25.21
Tangible Book Value	2,674	886.24	817.73	1,379	2,785	2,609
Tangible Book Value Per Share	10.10	5.40	6.10	11.73	23.68	25.10
Machinery	1,316	1,089	982.54	975.18	889.53	884.87
Construction In Progress	371.95	44.34	83.71	72.82	53.8	48.78
Leasehold Improvements	573.26	509.94	415.69	388.62	318.95	322.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.